| Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. | |
| | |
MedLine Citation:
|
PMID: 2555106 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. Hypertension is a complication of autologous bone marrow transplantation when therapy includes multiple alkylating agents. We have sought to identify the factors underlying this hypertension. We measured weight, serum creatinine, plasma renin activity, aldosterone and digoxin-like immunoreactive factor (DLIF), by digoxin radioimmunoassay, in 18 patients. Plasma catecholamines were also measured in five patients. 2. Of the 18 patients studied, 15 became hypertensive. The variable most consistently associated with these individuals' hypertension was DLIF activity which was increased in 14 of the 15 hypertensive patients (P = 0.055, Fisher exact test). Serum creatinine was increased at some point in seven of the 15 hypertensive patients, weight was increased in five and plasma renin activity and aldosterone were increased in one. Catecholamines were not increased in any of the five patients in which they were measured. 3. The association between changes in mean arterial pressure (MAP) and changes in DLIF for the group as a whole was assessed by analysing one data pair per patient, representing the maximal MAP. This correlation was significant (r = 0.75, P = 0.001). 4. Within individual patients, changes in MAP and changes in serum DLIF concentrations were significantly correlated (r greater than 0.50, P less than 0.05) in six of 15 hypertensive patients. 5. Digitalis-like factor (DLF) was measured by inhibition of (Na+,K+)-adenosine 5'-triphosphatase in five patients and DLF and DLIF were significantly correlated (r = 0.081, P = 0.0001). DLF and MAP were also significantly correlated (r = 0.59, P = 0.002). 6. This represents the first longitudinal study of the relationship between DLIF and blood pressure in hypertensive individuals, and the results suggest that DLIF may contribute to the increased blood pressure in some of these subjects. |
| | |
Authors:
|
S W Graves; J P Eder; S M Schryber; K Sharma; A Brena; K H Antman; W P Peters |
Related Documents
:
|
20361196 - Unrecognized secondary causes of hypertension in patients with hypertensive urgency/eme... 10852446 - Severity of hypertension in familial hyperaldosteronism type i: relationship to gender ... 6853676 - Basic and clinical reevaluation of tyramine and histamine tests for the investigation o... 8077576 - Systemic effects of ingesting varying amounts of a commercial carbohydrate beverage pos... 15834296 - Opposite effects of losartan and atenolol on natriuretic peptides in patients with hype... 6831746 - Hemodynamic actions of diuretic agents. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Clinical science (London, England : 1979) Volume: 77 ISSN: 0143-5221 ISO Abbreviation: Clin. Sci. Publication Date: 1989 Nov |
Date Detail:
|
Created Date: 1990-01-11 Completed Date: 1990-01-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7905731 Medline TA: Clin Sci (Lond) Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 501-7 Citation Subset: IM |
Affiliation:
|
Division of Endocrinology and Hypertension, Brigham and Women's Hospital, Boston, MA 02115. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aldosterone / blood Alkylating Agents / adverse effects Antineoplastic Combined Chemotherapy Protocols / adverse effects*, therapeutic use Blood Proteins / metabolism* Bone Marrow Transplantation* Cardenolides Carmustine / administration & dosage Cisplatin / administration & dosage Cyclophosphamide / administration & dosage Digoxin* Female Humans Hypertension / blood, chemically induced* Male Renin / blood Saponins* Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors* |
| Grant Support | |
ID/Acronym/Agency:
|
P50 HL 33697/HL/NHLBI NIH HHS; R01 HD 24499/HD/NICHD NIH HHS; R23 HD 21316/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Alkylating Agents; 0/Blood Proteins; 0/Cardenolides; 0/Saponins; 0/digoxin-like factors; 154-93-8/Carmustine; 15663-27-1/Cisplatin; 20830-75-5/Digoxin; 50-18-0/Cyclophosphamide; 52-39-1/Aldosterone; EC 3.4.23.15/Renin; EC 3.6.3.9/Sodium-Potassium-Exchanging ATPase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation,...
Next Document: Effects of endothelin on systemic and renal haemodynamics and neuroendocrine hormones in conscious d...